Skip to main content

Table 2 Multivariate analysis regarding the outcomes event-free survival (EFS), overall survival (OS) and rate of complete or unconfirmed complete remission (CR/CRu).

From: Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma

  EFS p-value HR (95% CI) OS p-value HR (95% CI) CR/Cru p-value OR (95% CI)
aaIPI score (0-1 vs. 2-3) <0.001 0.32 (0.17, 0.57) <0.001 0.28 (0.14, 0.56) <0.001 4.58 (1.96, 10.69)
CD4 (≥100 vs. < 100/μL <0.001 0.42 (0.26, 0.69) <0.001 0.37 (0.22, 0.63) <0.05 2.70 (1.26, 5.79)
R-EPOCH vs. R-CHOP <0.01 0.40 (0.23,0.69) <0.01 0.38 (0.21, 0.69) 0.117 1.90 (0.85, 4.22)